

Prepared in accordance with section 15 of the Broader Public Sector Accountability Act, 2010 (BPSAA)

TO: The Board of Trillium Health Partners, (the “Board”)
FROM: Karli Farrow
President & Chief Executive Officer
Trillium Health Partners
Date: June 6th, 2024
RE: April 1, 2023 to March 31, 2024

On behalf of Trillium Health Partners (the Hospital) I attest, with best efforts, to:

- the completion and accuracy of reports required of the Hospital pursuant to section 6 of the BPSAA on the use of consultants;
- the Hospital’s compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;
- the Hospital’s compliance with any applicable expense claims directives issued under section 10 of the BPSAA by the Management Board of Cabinet;
- the Hospital’s compliance with any applicable perquisite directives issued under section 15(1)(c.1) of the BPSAA by the Management Board of Cabinet; and
- the Hospital’s compliance with any applicable procurement directives issued under section 12 of the BPSAA by the Management Board of Cabinet,

during the Applicable Period.

In making this attestation, I have exercised care and diligence that would reasonably be expected of a Hospital President and Chief Executive Officer in these circumstances, including making due inquiries of Hospital staff that have knowledge of these matters including THP’s Chief Financial Officer, Senior Leadership, Controller, and Legal Counsel.


I further certify that any material exceptions to this attestation are documented in the attached Schedule A.

Dated at Mississauga, Ontario this June 6, 2024.



Karli Farrow
President and Chief Executive Officer
Trillium Health Partners

I certify that this attestation has been approved by Trillium Health Partners’ Board of Directors on June 6, 2024.



Christine Magee
Board Chair
Trillium Health Partners

SCHEDULE A to Attestation

1. Exceptions to the completion and accuracy of reports required in section 6 of the BPSAA on the use of consultants;

No Known Material Exceptions

Please see THP Hospital Reporting on Consultant Use.

2. Exceptions to the Hospital's compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;

No Known Material Exceptions

3. Exceptions to the Hospital's compliance with the expense claims directive issued under section 10 of the BPSAA by the Management Board of Cabinet;

No Known Material Exceptions

4. Exceptions to the Hospital's compliance with the perquisites directives issued under section 15(1)(c.1) of the BPSAA by the Management Board of Cabinet;

No Known Material Exceptions

5. Exceptions to the Hospital's compliance with the procurement directive issued under section 12 of the BPSAA by the Management Board of Cabinet,

Please see Shared Service West BPS Attestation reporting package for exceptions to Procurement Directives including 3rd party BPS attestations from THP's supply chain partners



March 31, 2024

Karli Farrow

President & CEO
Trillium Health Partners
2200 Eglinton Avenue West,
Mississauga, ON L5M 2N1

Dear Ms. Farrow:

Compliance with the Broader Public Sector Procurement Directive and applicable trade agreements

We provide this letter in connection with compliance of **Trillium Health Partners'** ("you", "your" or "Hospital") procurement contracts administered and completed by **Shared Services West** ("SSW" or "us") from **April 1, 2023 to March 31, 2024** ("the Applicable Period") with the Broader Public Sector Procurement Directive issued under Section 12 of the *Broader Public Sector Accountability Act* by the Management Board of Cabinet and the applicable trade agreements (i.e., Canada Free Trade Agreement and Canada-European Union Comprehensive Economic and Trade Agreement), all jointly referred to hereinafter as the "**Procurement Directive**".

For procurements (including redevelopment contracts) partly managed by SSW during the Applicable Period, this attestation applies only to the portion of the work performed by us. For contracts that you participated in, completed by HealthPRO and other shared services and procurement organizations ("**Other SSO**"), the attestations of HealthPRO and the Other SSOs relating to such contracts are attached at Appendix 2 to 4.

In making this attestation, we have exercised care and diligence that would reasonably be expected of a **President & CEO, Vice President, Finance & Integration and Vice President, Sourcing, Operations & Member Engagement**, in these circumstances, including reviewing our internal compliance framework, making due inquiries of staff that have knowledge of these matters, internal attestations received from our sourcing management staff, and the results of an internal review conducted by us of a sample drawn from all contracts completed by SSW during the Applicable Period ("**the Review**").

Procurement Directive compliance:

- We have completed procurement contracts for goods and services, including consulting services, on your behalf in accordance with the Procurement Directive to the extent of its applicability to our work, and will be providing you a list of all our findings resulting from the Review. The scope of the Review and material exceptions to the Procurement Directive noted are comprised in the attached Appendix 1.

Policy compliance:

- We acknowledge that we are responsible for ensuring that your contracts are executed in compliance with the Procurement Directive and your specific policies, and have designed and implemented an internal control framework to prevent and detect deviations therefrom.
- We have taken steps to retain all material documentation, information, and communication related to the procurement processes, in a recoverable format, in accordance with the Procurement Directive and your policies.

Communications from Government authorities:

- There have been no communications from the Ministry of Finance or any other regulatory or government agency concerning non-compliance, or potential deficiencies in compliance, with the Procurement Directive or any other related legislated directive or policy.

Potential legal disputes:

- In relation to the procurements completed by us on your behalf, we've informed your Chief Financial Officer of any significant bid disputes or other matters which could potentially expose you to legal risk or contingent liabilities immediately upon learning of the same. All of them were satisfactorily resolved during the Applicable Period.

The following listings are provided in the attached appendices:

1. Material exceptions – Appendix 1
2. Attestation from HealthPRO - Appendix 2
3. Attestation from MMC - Appendix 3; and
4. Attestation(s) from other agencies - Appendix 4

A list of consulting services contracts has been provided to you separately.

Yours truly,

Karen Belaire (May 6, 2024 17:05 EDT)

Karen Belaire
President & CEO

Kyle Watts (May 6, 2024 16:43 EDT)

Kyle Watts
Vice President, Finance & Integration

Appendix 1

Material Exceptions

Note: Terms used in this Appendix are either defined herein or in the accompanying attestation letter.

Scope - Defined

We conducted an internal review (“**the Review**”) of a sample comprising forty-nine contracts drawn from all the contracts managed and completed by us during the Applicable Period. The contracts comprised in the sample were selected based on their spend value and complexity, and in terms of the audit plan approved by SSW’s Board of Directors. Results of the Review are provided in Part-A below. Our findings, conclusions and comments are based solely on our review of this sample.

Scope - Exclusion

The scope of the Review excluded testing compliance with the following Mandatory Requirements (MR), since the accountability of all the aspects thereof do not fully vest in SSW:

MR #1 – Hospital Segregation of Duties:

- Organizations must segregate at least three of the five functional procurement roles: Requisition, Budgeting, Commitment, Receipt and Payment. Responsibilities for these roles must lie with different departments or, at a minimum, with different individuals. Where it is not feasible to segregate these roles, i.e., for smaller organizations, adequate compensating controls approved by an external auditor must be put in place.

MR #2 – Establishment of the Approval Authority:

- Organizations must establish an approval authority schedule (AAS) for procurement of goods and non-consulting services. The AAS must be approved by the Board of Directors of the organization or its equivalent prior to commencement of procurement.

MR #22 – Contract Management:

- Payments must be made in accordance with provisions of the contract. All invoices must contain detailed information sufficient to warrant payment. Any overpayments must be recovered in a timely manner.
- Establish expense claim and reimbursement rules compliant with the Broader Public Sector Expenses Directive and ensure all expenses are claimed and reimbursed in accordance with these rules.
- Ensure that expenses are claimed and reimbursed only where the contract explicitly provides for reimbursement of expenses.

Appendix 1

Material Exceptions

General Observations

In a few cases, the Review found some documents had not been retained by SSW after completion of the procurement process. Corroborating evidence was however found elsewhere to support compliance of such contracts with the Procurement Directive.

Procurements conducted in the following circumstances were so conducted for compelling business reasons and have not been individually listed herein:

1. In terms of the evolving Provincial agenda, several shared services organizations in Ontario are working collaboratively to consolidate contracts for certain high-value products. SSW too has aligned the end date of some of its agreements with the expected start dates of these consolidated contracts, resulting in exceptions to MR #18 (term of agreement modifications) for such contracts identified during the Review. Such harmonization has generally preserved the current pricing and supply continuity to the participating hospitals (including you).
2. Though the worldwide pandemic was declared over by the World Health Organization, there are lasting impacts on the procurement and sourcing approaches for the Hospital. Some of the procurements conducted were so conducted due to externalities that necessitated deferral of the competitive procurement process of several agreements. These agreements were put in place and/or amended to allow for such processes to be completed subsequently, sometimes resulting in exceptions to MR #3 (competitive procurement thresholds) and/or MR #18 (term of agreement modifications).
3. The Canadian Free Trade Agreement requires public posting of award notice for Limited Tender procurements. In certain cases, including the foregoing, such posting was delayed beyond the prescribed time periods.

Appendix 1
Material Exceptions

Exceptions Noted

Part A: Following material exceptions were identified as a result of the Review of the sample referred to above:

Contract ID	Contract Description	Procurement Type	Vendor Name	Term + Option (years)	Estimated Non-Compliance	MR #	Comments
204399	Peritoneal Dialysis Home Service	Non-Competitive	Baxter & Fresenius	3+2 years	\$33,057,000	3, 21	Due to continued challenges in the market for these products, and to secure best value for its members, the provincial procurement strategy chosen by the collaborative partners resulted in direct negotiations with the suppliers instead of conducting an open competitive process.
205994	Electrophysiology Products Supply	Non-Competitive	Abbott Medical, Medtronic, Johnson & Johnson, Teleflex	2+2 years	\$9,322,000	3, 21	Due to the backlog of cardiac procurement initiatives during the Covid-19 pandemic, and to secure best value for its members, the provincial strategy chosen by the collaborative partners resulted in direct negotiations with the suppliers instead of conducting an open competitive process.
207259	General Medical & Surgical Product Supply	Non-Competitive	Cardinal Health Canada	4 years	\$3,178,000	3, 18, 21	Non-competitive contract extension was executed, a result of a regional approach to align the terms of the competitive processes for the <i>Distribution & Warehouse Service</i> and the <i>General Medical & Surgical Products Supply</i> . Due to the complexity of a transition to a new vendor, a change of supplier could not be made for economic and technical reasons and would have caused disruption of service and substantial duplication of costs for the Hospital.

Appendix 1
Material Exceptions

Contract ID	Contract Description	Procurement Type	Vendor Name	Term + Option (years)	Estimated Non-Compliance	MR #	Comments
165598	ICAT Advisory Services for THP Broader Redevelopment Project	Non-Competitive - Amendment	HH Angus Associates Limited	13 years	\$1,960,000	3, 18, 21	Due to changes in government direction, changes in project timelines impacted the delivery of the ICAT Advisory Services. A change of supplier could not be made for economic and technical reasons and would have caused disruption of service and substantial duplication of costs for the Hospital.
204113	Prime Architectural Consultant for Q-Site BF Patient Tower	Non-Competitive - Amendment	Stantec Architecture Ltd	5+5+5 years	\$1,500,000	3, 21	Given inflationary pressures since 2020, the supplier's hourly rates for 2023 and 2024 increased to reflect current market conditions. A change of supplier could not be made for economic and technical reasons and would have caused disruption of service and substantial duplication of costs for the Hospital.
159522	Document Scanning	Non-Competitive	Salumatics Inc.	2 years	\$724,000	3, 18, 21	To allow time for evaluation of the future business requirements, a two-year extension was put in place. A change of supplier could not be made for economic and technical reasons and would have caused disruption of service and substantial duplication of costs for the Hospital.
208526	Arrow Catheter Epidurals Needles Trays	Non-Competitive	Teleflex Medical Canada	2+2 years	\$375,000	3, 21	These products under previously existing contract with the supplier, were clinically proven to significantly reduce patient risks as compared to other alternatives. After assessing existing affiliation contracts, to secure best value for the Hospital and to mitigate patient risks, this contract was put in place with direct negotiations with the supplier.
205976	Palo Alto Security Solution	Open competitive - Piggyback	CDW Canada	1.25 + 1 years	\$154,000	2, 3, 21	To further strengthen Hospital's IT security capabilities, additional security subscriptions were added to the piggyback agreement which were not included in the prime agreement. For this non-competitive amendment, appropriate approval on a Limited Tender form was not documented.

Appendix 1

Material Exceptions

Part-B: To maximize value for money and for the hospital's benefit, purchases under the following contracts commenced after all the terms and conditions of the contract had been finalized but before it was formally signed and/or terms and conditions of the expiring contracts were maintained while procurement process was being conducted for the new contract (MR#15: Executing the contract). The delayed timing, in some cases, were a result of protracted negotiations to get best value, short notice of additional funding/planning issues and competing priorities with available resources while ensuring patient care.

Contracts with significant gaps between first purchase and formal execution are provided in the table below:

Contract ID	Contract Description	Vendor Name	Contract Completion Year (Actual/Estimated)	Estimated Current Year Spend Until Contract Signature
204345	General Laboratory Supplies	Multiple vendors	FY23/24	\$2,265,000
165281	Product supply for Intra Ocular Lenses	Multiple vendors	FY23/24	\$2,077,000
205994 **	Electrophysiology products supply	Abbott, Medtronic, Johnson and Johnson & Teleflex	FY23/24	\$2,049,000
202703**	Interventional Cardiology Product Supply	Multiple vendors	FY23/24	\$1,785,000
204399	Peritoneal Dialysis Home Service	Baxter & Fresenius	FY23/24	\$828,000
206216	NGS Kits for Hereditary Cancer Testing	Sophia Genetics SA	FY23/24	\$790,000
206158	Stationery Products, Bond Paper, and Toner Products	Staples, Grand N Toy, Ariva	FY23/24	\$771,000
211704	Prismaflex Agreement	Baxter Canada	FY23/24	\$430,000
208483	Product supply for Arthroplasty Shoulders	Zimmer Biomet & Johnson and Johnson	FY23/24	\$262,000
206002	OR Hemodynamic Monitoring Products	Edwards Lifesciences (Canada) Inc	FY23/24	\$220,000
166282	Communications Services	Curious Public Content and Insights	FY23/24	\$214,000



Appendix 1

Material Exceptions

Contract ID	Contract Description	Vendor Name	Contract Completion Year (Actual/Estimated)	Estimated Current Year Spend Until Contract Signature
207259 **	General Medical Surgical Distributor	Cardinal Health Canada	FY23/24	\$181,000
209663	Meditech Annual Support	Medical Information Technology	FY23/24	\$112,000

Notes:

** Spend between first purchase and formal execution of the contract for FY22/23:

- 205994: Electrophysiology products supply: \$1,895K
- 207259: General Medical Surgical Distributor: \$647K
- 202703: Interventional Cardiology Product Supply: \$584K

Abbreviations:

- MR#2: Approval Authority
- MR#3: Competitive procurement thresholds
- MR#5: Supplier Pre-Qualification
- MR#18: Term of Agreement Modifications
- MR#21: Non-competitive procurement



April 17, 2024

Karli Farrow
President and Chief Executive Officer
Trillium Health Partners - All Sites
2200 Eglinton Ave. West
Mississauga, ON L5M 2N1

Dear Ms. Farrow:

Re: Ontario Ministry of Finance Broader Public Sector (BPS) Procurement Directive

Thank you for your continued support of HealthPRO Canada (HealthPRO) and your participation in our contracts. As your national group contracting provider for healthcare, we understand it is important that our contracting processes comply with national and provincial agreements.

We have reviewed our contracting processes and documents and can attest to HealthPRO's compliance to the Ontario Broader Public Sector Act Procurement Directive for the fiscal year 2023/24.

To support our category management approach to procurement, HealthPRO may occasionally extend contracts to align expiry dates in order to deliver maximum value for our members. When a decision is made to extend a contract/s, it is required by the Broader Public Sector (BPS) Procurement Directive that such extensions be reported as exceptions.

There are no extensions to report for the 2023/24 fiscal year.

If you require additional information, please contact Ms. Kendra Frey, Vice President of Materials Management (289-805-7920) or Ms. Nancy Giovinazzo, Interim Vice President of Pharmacy (289-805-7869).

Yours sincerely,

A handwritten signature in black ink, appearing to read "CDonaldson", written in a cursive style.

Christine Donaldson
Interim President & CEO
HealthPRO Procurement Services Inc.



April 1, 2024

Attestation to the BPSAA Supply Chain Secretariat BPS Directive and Canada Free Trade Agreement (CFTA) Compliance

Dear Member,

Mohawk Medbuy Corporation fully understands and abides by the Ontario Ministry of Finance Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA) meant to ensure that publicly funded goods and services are acquired by BPS organizations through a process that is open, fair, and transparent.

On behalf of Mohawk Medbuy Corporation, we attest that all contracting services performed on the Members' behalf for the applicable period of April 1, 2023 – March 31, 2024, are in compliance with the Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA). Exceptions, for contracts on which the Member participated occurring during the twelve (12) month reporting period are noted on the attached document with supporting explanations.

In making this attestation, we have exercised care and diligence that would reasonably be expected in these circumstances, including making due inquires and reviewing results of the self-assessment audits we have completed.

I, Marc Lemaire, Senior Vice President, Sourcing, I, Dale Thomson, Senior Vice President, Sourcing, I, Raechel Griffin, Vice President, Capital, FFE, and Nutrition Services Procurement I, Ally Dhalla, Senior Vice President Pharmacy and Clinical Services & Innovation have the signing authority to make this commitment on behalf of Mohawk Medbuy Corporation.

MOHAWK MEDBUY CORPORATION

Handwritten signature of Marc Lemaire in black ink.

Marc Lemaire
Senior Vice President, Sourcing
mlemaire@mohawkmedbuy.ca

Handwritten signature of Dale Thomson in black ink.

Dale Thomson
Senior Vice President, Sourcing
dthomson@mohawkmedbuy.ca

Handwritten signature of Raechel Griffin in black ink.

Raechel Griffin
Vice President, Capital, FFE
and Nutrition Services
Procurement
rgriffin@mohawkmedbuy.ca

Handwritten signature of Ally Dhalla in black ink.

Ally Dhalla
Senior Vice President, Pharmacy and Clinical Services & Innovation
adhalla@mohawkmedbuy.ca



BPS Attestation Report - April 1, 2023 to March 31, 2024 - SSW

Code	Contract No.	Contract Name	Supplier Name	Contract Start Date	Current Contract Expiry Date	New Contract Expiry Date (for extended contracts)	Exception Type	Justification Code	TRILLIUM HEALTH PARTNERS
MILR	C12187	MILR LAB PROFICIENCY TESTING 2023	College of American Pathologist	9/1/2023	8/31/2028		Limited Tender	A5	P-ND
MMCL	C12042	MMCL DENTAL PRODUCTS 2021	Henry Schein	8/1/2023	7/31/2025		Limited Tender	A1	P-ND
MMCL	C12044	MMCL DENTAL PRODUCTS 2021	Patterson Dental	8/1/2023	7/31/2025		Limited Tender	A1	P-ND
MMNCL	C11635	MMNCL Outsourced Sourcing Services	Ayres Consulting Services	4/25/2023	10/24/2023		Limited Tender	A7 (i)	P-ND
PH	C12000	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	AbbVie	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11972	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Accellor	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10858	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Alcon	6/1/2023	1/31/2024		Limited Tender	A7(ii)	\$1,680
PH	C11916	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Alera Skin Care	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11992	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	AMG Medical	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11969	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Apotex Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11963	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Aspen Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10862	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	AstraZeneca	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12007	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Atlas Lab	6/1/2023	1/31/2024		Limited Tender	A7(ii)	\$1,617
PH	C11991	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Auro Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11947	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Bausch & Lomb	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11948	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Bausch Health, Canada Inc,	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10866	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Bayer	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11949	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Biosyent	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12008	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Boehringer-Ingelheim (Canada)	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12053	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	BGP Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11922	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Dr. Reddy's Laboratories Canada Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12120	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Ferring Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11171	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Galenova	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10870	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Generic Medical	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12040	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Healthmark	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10876	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	JAMP Pharma Corporation	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11923	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Johnson & Johnson Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11950	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Leo Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11951	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Medexus Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C10873	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Merck Canada Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12003	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Mylan Pharmaceuticals	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11952	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Natco Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11967	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Norwell Consumer Healthcare	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11980	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Novartis Pharmaceuticals Canada Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11981	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Odan Laboratories Ltd	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11982	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Omega Lab	6/1/2023	1/31/2024		Limited Tender	A7(ii)	\$80
PH	C11924	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Organon Canada	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11925	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Orimed Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12081	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Paladin Labs	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11928	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Pendopharm	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12006	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Pharma stulln	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11954	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Pharmascience Inc,	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11984	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Sandoz Canada Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12118	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	sanofi-aventis Canada Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C12117	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	saonfi Consumer	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11985	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Seaford Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11987	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Searchlight Phama	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11926	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Sterimax Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11971	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Stom Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11994	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Taro Pharmaceuticals	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11988	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Valeo Pharma Inc	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11145	PH Non Injectable Non-Oral Solid Pharmaceuticals - Bridge	Xediton Pharma	6/1/2023	1/31/2024		Limited Tender	A7(ii)	P-ND
PH	C11869	PH Oral Solid Pharmaceuticals - Bridge	AbbVie	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11870	PH Oral Solid Pharmaceuticals - Bridge	Accel Pharma Inc.	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C10544	PH Oral Solid Pharmaceuticals - Bridge	Astellas Pharma Canada	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11873	PH Oral Solid Pharmaceuticals - Bridge	Auropharma Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C10570	PH Oral Solid Pharmaceuticals - Bridge	Bausch Health, Canada Inc,	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11875	PH Oral Solid Pharmaceuticals - Bridge	Bayer	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11876	PH Oral Solid Pharmaceuticals - Bridge	BGP Pharma	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11877	PH Oral Solid Pharmaceuticals - Bridge	Boehringer-Ingelheim (Canada)	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11878	PH Oral Solid Pharmaceuticals - Bridge	Dr. Reddy's Laboratories Canada Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C10550	PH Oral Solid Pharmaceuticals - Bridge	Eli Lilly Canada Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11881	PH Oral Solid Pharmaceuticals - Bridge	Johnson & Johnson Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11882	PH Oral Solid Pharmaceuticals - Bridge	Marcan Pharmaceuticals Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11883	PH Oral Solid Pharmaceuticals - Bridge	Medexus Pharma	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11884	PH Oral Solid Pharmaceuticals - Bridge	Merck Canada Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11885	PH Oral Solid Pharmaceuticals - Bridge	Mint Pharmaceuticals Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11886	PH Oral Solid Pharmaceuticals - Bridge	Mylan Pharmaceuticals	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11887	PH Oral Solid Pharmaceuticals - Bridge	Natco Pharma	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11892	PH Oral Solid Pharmaceuticals - Bridge	Norwell Consumer Healthcare	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11888	PH Oral Solid Pharmaceuticals - Bridge	Novartis Pharmaceuticals Canada Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11889	PH Oral Solid Pharmaceuticals - Bridge	Odan Laboratories Ltd	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11890	PH Oral Solid Pharmaceuticals - Bridge	Paladin	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11891	PH Oral Solid Pharmaceuticals - Bridge	Pendopharm	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11893	PH Oral Solid Pharmaceuticals - Bridge	Pfizer Canada ULC	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11894	PH Oral Solid Pharmaceuticals - Bridge	Pharmascience Inc,	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND

PH	C11897	PH Oral Solid Pharmaceuticals - Bridge	Searchlight Phama	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11898	PH Oral Solid Pharmaceuticals - Bridge	Taro Pharmaceuticals	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11900	PH Oral Solid Pharmaceuticals - Bridge	Valeo Pharma Inc	7/1/2023	3/31/2027		Limited Tender	A7(ii)	P-ND
PH	C11871	PH Oral Solid Pharmaceuticals	Apotex Inc	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C11872	PH Oral Solid Pharmaceuticals	Astellas Pharma Canada	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12167	PH Oral Solid Pharmaceuticals	Eisai Co	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C11880	PH Oral Solid Pharmaceuticals	JAMP Pharma Corporation	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12230	PH Oral Solid Pharmaceuticals	HLS Therapeutics	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12192	PH Oral Solid Pharmaceuticals	Indivior Canada	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12275	PH Oral Solid Pharmaceuticals	Lupin	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12185	PH Oral Solid Pharmaceuticals	Organon Canada	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C11896	PH Oral Solid Pharmaceuticals	sanofi-aventis Canada Inc	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C11895	PH Oral Solid Pharmaceuticals	Sandoz Canada Inc	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C11899	PH Oral Solid Pharmaceuticals	Teva Canada Ltd	7/1/2023	3/31/2027		Limited Tender	A2 & A5	P-ND
PH	C12213	PH Inhaled Anaesthetics Desflurane 2023	Baxter	10/1/2023	9/30/2026		Limited Tender	A5	P-ND
PH	C11221	PH Clozapine 2023	Eli Lilly Canada Inc	10/1/2023	9/30/2025		Limited Tender	A5	P-ND
PH	C12225	PH Clozapine 2023	HLS Therapeutics	10/1/2023	9/30/2025		Limited Tender	A5	P-ND
PH	C12227	PH Clozapine 2023	Mylan Pharmaceuticals	10/1/2023	9/30/2025		Limited Tender	A5	P-ND
PH	C12157	PH NAPRA Quality Compliance and Risk Management System 2023	Omnitech	12/1/2023	11/30/2026		Limited Tender	A5	P-ND
PH	C12156	PH NAPRA Quality Compliance and Risk Management System 2023	Innovative OncoSolutions	12/1/2023	11/30/2026		Limited Tender	A5	P-ND
PH	C12406	PH Drug Information Services 2024	METRODIS	1/1/2024	12/31/2028		Limited Tender	A5	P-ND
PH	C12405	PH Drug Information Services 2024	THE NORTH WEST COMPANY LP. OVRDIS	1/1/2024	12/31/2027		Limited Tender	A5	P-ND
PH	C11594	PH MISCELLANEOUS ONCOLOGY + INJECTABLE PHARMACEUTICALS SEPT 2023	Avir Pharma	1/1/2024	9/30/2024		Limited Tender	A2 & A5	P-ND
PH	C11220	PH MISCELLANEOUS ONCOLOGY + INJECTABLE PHARMACEUTICALS SEPT 2023	Pharmascience	1/1/2024	9/30/2025		Limited Tender	A2 & A5	P-ND
PH	C12538	PH Oncology Biologic HLR- LT	Hoffmann-La Roche	2/15/2024	10/31/2026		Limited Tender	A5	P-ND
MMNCL	C10500	MMNCL CHEMICALS - DIETARY & LAUNDRY 2019 - BUNZL	BUNZL	9/1/2019	8/31/2023	9/1/2023	Extension	A8	\$5,293
MILR	C11553	MILR CONTRAST MEDIA BARIUM 2023 - BRACCO - PA	BRACCO IMAGING CANADA	1/1/2023	12/31/2022	12/31/2025	Extension	A5 (iii)	\$8,154
MILR	C11626	MILR REAGENTS LAB RESEARCH 2023 - QIAGEN INC	QIAGEN INC	1/1/2023	12/31/2022	12/31/2024	Extension	A5 (v)	\$51,948
MMNCL	C9072	MMNCL Non Woven Wraps - Cardinal	Cardinal Health	10/1/2016	3/31/2023	9/30/2023	Extension	A8	\$8,174
MILR	C8808	MILR Contrast Media 2015 - GE	GE	11/1/2015	7/31/2023	8/31/2023	Extension	A8	\$314,048
MILR	C8810	MILR Contrast Media 2015 - Bracco	Bracco	11/1/2015	7/31/2023	8/31/2023	Extension	A8	\$42,930
MILR	C8811	MILR CONTRAST MEDIA 2015 - LANTHEUS	Lantheus	11/1/2015	7/31/2023	8/31/2023	Extension	A8	\$167,384
MMNCL	C8835	MM REUSABLE HAZARDOUS WASTE CONTAINERS AND SERVICE 2016 - DANIELS	Daniels	3/1/2016	8/31/2023	12/31/2023	Extension	A8	\$681,853
OR	C8904	OR TRAUMA AND BONE FIXATION PRODUCTS - CRANIAL MAXILLOFACIAL PLATE AND SCREW SYSTEMS 2016 - JJMP	JJMP	4/1/2016	12/31/2023	8/31/2025	Extension	A8	P-ND
OR	C8907	OR TRAUMA AND BONE FIXATION PRODUCTS - CRANIAL MAXILLOFACIAL PLATE AND SCREW SYSTEMS 2016 - ZIMMER	ZIMMER BIOMET	4/1/2016	12/31/2023	8/31/2025	Extension	A8	\$128,821
MILR	C8590	MILR SPECIALTY AND BIOPSY NEEDLES 2015 - BARD	BARD	4/1/2015	12/31/2023	1/31/2024	Extension	A (d)	\$142,125
MILR	C8593	MILR SPECIALTY AND BIOPSY NEEDLES 2015 - DEVICOR	DEVICOR	4/1/2025	12/31/2023	3/31/2024	Extension	A a (i), d	\$73,520
MMNCL	C8955	MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 - ASP	Advanced Sterilization	5/1/2016	11/30/2023	11/30/2024	Extension	A (d)	\$36,639
OR	C9075	OR ANESTHESIA TRAYS AND NEEDLES 2016 - CHS	CHS	10/1/2016	11/30/2023	2/15/2024	Extension	A (d)	\$124,125
MMCL	C10456	MMCL SUCTION DEVICES 2019 - INSTRUMED - PA	Instrumed	2/1/2019	1/31/2024	3/31/2024	Extension	(d)	P-ND
MILR	C10472	MILR LABORATORY SUPPLIES 2019 - MICRONOSTYX	Micronostyx	5/1/2019	4/30/2024	4/30/2026	Extension	A (d)	\$32,811

* Reported Spend incidates Member provided data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 1 2022 to September 30 2023

P - ND indicates Member participation on contract, however spend data not provided/available.
NP - Not Participating

APPENDIX A – Limited Tendering Exception Codes	
<p>A1. If no tenders were submitted or no suppliers requested participation</p> <p>A2. If no tenders that conform to the essential requirements of the tender documentation were submitted</p> <p>A3. If no suppliers satisfied the conditions for participation</p> <p>A4. If the submitted tenders were collusive</p> <p>A5. If the goods and services can be supplied only by a particular supplier and no reasonable alternative or substitute goods or services exist for any of the following reasons:</p> <ul style="list-style-type: none"> (i) Requirement is for a work of art (ii) Protection of patents, copyrights or other exclusive rights (iii) Due to an absence of competition for technical reasons (iv) Supply of goods or services is controlled by a supplier that is a statutory monopoly (v) To ensure compatibility with existing goods, or to maintain specialized goods that must be maintained by the manufacturer of those goods or its representative (vi) Work is to be performed on property by a contractor according to the provisions of a warranty or guarantee held in respect of the property or the original work (vii) Work is to be performed on a leased building or related property, or portions thereof, that may be performed only by the lessor (viii) Subscriptions to newspapers, magazines or other periodicals <p>A6. If goods or consulting services regarding matters of a confidential or privileged nature are to be purchased and the disclosure of those matters through an open tendering process could reasonably be expected to compromise government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest</p>	<p>A7. For additional deliveries by the original supplier of goods or services that were not included in the initial procurement, if a change of supplier for such additional goods or services:</p> <ul style="list-style-type: none"> (i) Cannot be made for economic or technical reasons such as requirements of interchangeability or interoperability with existing equipment, software, services or installations procured under the initial procurement; and (ii) Would cause significant inconvenience or substantial duplication of costs for the procuring entity <p>A8. If strictly necessary, and for reasons of urgency brought about by events unforeseeable by the procuring entity, the goods or services could not be obtained in time using open tendering</p> <p>A9. Goods purchased on a commodity market</p> <p>A10 If a procuring entity procures a prototype or a first good or service that is developed in the course of, and for, a particular contract for research, experiment, study, or original development. Original development of a first good or service may include limited production or supply in order to incorporate the results of field testing and to demonstrate that the good or service is suitable for production or supply in quantity to acceptable quality standards, but does not include quantity production or supply to establish commercial viability or to recover research and development costs</p> <p>A11. For purchases made under exceptionally advantageous conditions that only arise in the very short term in the case of unusual disposals such as those arising from liquidation, receivership, or bankruptcy, but not for routine purchases from regular suppliers</p> <p>A12. If a contract is awarded to a winner of a design contest provided that: (i) the contest has been organized in a manner that is consistent with the principles of this Chapter, in particular relating to the publication of a tender notice; and (ii) the participants are judged by an independent jury with a view to a design contract being awarded to a winner.</p>

TO: Shared Services West
Burlington, ON.

FROM: Nils Clausen
Chief Executive Officer (CEO)
CMEPP - Canadian Medical Equipment Protection Plan

Date: April 16, 2024

Re: Canadian Medical Equipment Protection Plan (the “CMEPP”)
Re: Compliance with Broader Public Sector Procurement Directive (the “Directive”)

Organizations that participate in group purchasing activities through buying groups and other procurement services organizations must ensure that the activities of these entities are carried out in a manner consistent with the Directive.

For the fiscal year 2023/2024, acting in accordance with the instructions and information received from your hospital/organization, CMEPP conducted its procurement activities on your behalf in a manner that is compliant with the Directive.

In stating so, CMEPP exercised care and diligence that would be reasonably expected of a CEO in these circumstances, including making due inquiries of CMEPP personnel that have knowledge of these matters.

Yours truly,



Nils Clausen
Chief Executive Officer

April 17, 2024

Mohawk Medbuy
Tawfique Aziz
Manager, Compliance and Financial Analytics
905-287-2870 ext 159

Dear Tawfique Aziz,

Kinetic GPO is providing this attestation letter to declare that all Kinetic GPO's procurement functions are in compliance with the Canadian Free Trade Agreement (CFTA) Chapter 5 and the Comprehensive Economic and Trade Agreement (CETA) Chapter 19 and of course the Broader Public Sector (BPS) Procurement Directive.

Our practices, policies and protocols have been prepared and reviewed by renowned Canadian procurement lawyers to ensure everything Kinetic does conforms with Canadian Common Law. Kinetic GPO employs senior procurement professionals with decades of experience working in the public sector, who prepare and review our documents, and who oversee each procurement process to ensure compliance with the rules.

Kinetic GPO's membership spans all of Canada, and although we can confirm compliance to the International, National and Regional trade agreements, we are unable to confirm compliance with each Member's local policies. Kinetic GPO is open to supporting our members who wish to learn more or to verify whether our policies, protocols and practices comply with the requirements of their own legal and policy framework.

The Ontario provincial government introduced the BPS Procurement Directive announcing their plan to deliver a Centralized Procurement Initiative for Ontario Public Service and Broader Public Sector (BPS) organizations. The purpose of the BPS Procurement Directive is to ensure the BPS entities have access to goods and services through fair, open and transparent competitions. The BPS Procurement Directive strives to ensure the BPS entities are consistently managing their procurement process as well the BPS Procurement Directive outlines the BPS entities responsibilities. In 2022 the province of Ontario also introduced the Building Ontario Business Initiative Act and in 2023 the federal government passed Bill S-211 (Forced labour in Canadian Supply Chains). Kinetic GPO has spoken to each of these in our competition documents as we constantly strive to ensure compliance.

Enclosed is a link to Kinetic GPO's website and our [Procurement Policies and Procedures section](#). If you have any questions, or require further information, please don't hesitate to contact me directly at carl@kineticgpo.ca or 306-525-4395.

Sincerely,

Carl Macdonald
Director of Contracting and Compliance
Kinetic GPO

Tawfique Aziz
Manager, Compliance and Financial Analytics
100-1107 Clay Avenue
Burlington, ON L7L 0A1
Mohawk Medbuy

April 17, 2024

Dear Tawfique,

As requested in your email dated April 16, 2024, the enclosed letter serves as an attestation that OECM conducts all sourcing initiatives in compliance with the Broader Public Sector (BPS) Procurement Directive as well as other trade agreements.

OECM, and the customers we serve follow the BPS Procurement Directive. The directive sets out rules for designated BPS entities on the purchase of goods and services using public funds.

The purpose of the directive is:

- To ensure that goods and services, including construction, consulting services, and information technology are acquired by BPS entities through a process that is open, fair, and transparent;
- To outline responsibilities of BPS entities throughout each stage of the procurement process; and,
- To ensure that all BPS entities in Ontario are consistently managing their procurement processes.

In addition, OECM's sourcing initiatives are undertaken within the scope of Chapter 5 of the Canadian Free Trade Agreement ("CFTA"), Chapter 19 of the Comprehensive Economic and Trade Agreement ("CETA"), and within the scope of the Trade and Cooperation Agreement between Quebec and Ontario.

I also enclose a link to the Ontario Tender's Portal (OTP) website where all of OECM's RFPs are posted: <https://ontariotenders.bravosolution.com/esop/nac-host/public/home.html>

Should you have any questions, or require further information, please don't hesitate to contact our Customer Support Team at customersupport@oecm.ca or 1-844-OECM-900 (1-844-632-6900).

Sincerely,

Karen Owen

Karen Owen
Senior Vice President, Strategy and Partnerships

Hospital Reporting on Consultant Use



Name of Hospital:

**Trillium Health
Partners**

Ontario Health:

Ontario Health Central

Reporting Period:

April 1, 2023 to March 31, 2024

No.	Consulting Firm (Name)	Name & Title of Consulting Contract	Contract Terms (Original plus renewals / amendments)	Procurement Value (Originals Plus renewals / amendments and TOTAL PAID)	Consulting Selection Process (Invitational competitive, open competitive, or non-competitive)	Any modifications to the agreement (Yes/No)?
1	Bass Associates; Emond Harnden LLP	Labour Relations Strategic Support (Multi-award)	March 1, 2019 to February 28, 2024	Total Procurement Value: \$500,000 plus tax Total Paid to Date: \$190,292	Open competitive	No modifications
2	Santis; Counsel Public Affairs; Rivet (2542060 Ontario Inc.); StrategyCorp, Curious Public Content and Insights	Crisis & Corporate Communications Services (Multi-award)	November 1, 2019 to October 31, 2024	Total Procurement Value: \$462,142.53 plus tax (includes consulting & non-consulting) Total Paid to Date: \$257,394	Open competitive, invitational competitive and non-competitive	Amended to exercise the option years. Amended to add additional scope.
3	LOH Architects Associates Inc.	Retail Strategy - Broader Redevelopment Project	December 1, 2018 to December 31, 2025	Total Procurement Value: \$330,550 plus tax (includes consulting and non-consulting) Total Paid to Date: \$224,553	Open competitive and non-competitive	Amended to include additional scope
4	KPMG Corporate Finance Inc.	Advisory Assistance for Financing Requirements	June 11, 2018 to June 10, 2026	Total Procurement Value: \$1,924,675 plus tax (includes consulting & non-consulting) Total Paid to Date: \$578,663	Open competitive	Amended to extend term
5	Cushman & Wakefield ULC, Brokerage	Commercial Real Estate Advisory Services	November 1, 2018 to October 31, 2025	Total Procurement Value: \$1,009,700 plus tax (includes consulting and non-consulting) Total Paid to Date: \$533,137	Open competitive	No modifications
6	Deloitte Inc.	THP Local Share Plan Consultant	December 11, 2020 to December 31, 2025	Total Procurement Value: \$469,000 plus tax Total Paid to Date: \$78,506	Open competitive	No modifications

No.	Consulting Firm (Name)	Name & Title of Consulting Contract	Contract Terms (Original plus renewals / amendments)	Procurement Value (Originals Plus renewals / amendments and TOTAL PAID)	Consulting Selection Process (Invitational competitive, open competitive, or non-competitive)	Any modifications to the agreement (Yes/No)?
7	Selectpath Benefits and Financial Inc.	HR Benefits Consulting Services	November 1, 2021 to October 31, 2026	Total Procurement Value: \$278,357 plus tax Total Paid to Date: \$190,090	Open competitive	No modifications
8	Janice Stein Consulting Services Ltd.	Advisory Services related to Departmental Review	June 1, 2022 to June 30, 2023	Total Procurement Value: \$23,000 plus tax Total Paid to Date: \$21,750	Non-competitive	Amended to include additional scope
9	ML Consulting	Pay Equity Services	September 1, 2022 to August 31, 2027	Total Procurement Value:\$99,938 plus tax Total Paid to Date: \$12,837	Invitational competitive	No modifications
10	Ernst & Young Global Limited	Financial Systems Advisory	August 15, 2022 to July 31, 2024	Total Procurement Value:\$125,000 plus tax Total Paid to Date: \$113,000	Open competitive	No modifications
11	StrategyCorp Inc.	Advisory Services for IT Road Map	March 8, 2023 to August 31, 2023	Total Procurement Value:\$75,216 plus tax Total Paid to Date: \$75,226	Invitational competitive	No modifications
12	Preyra Solutions Group	Capacity Planning and Peer Benchmarking	January 1, 2024to December 31, 2030	Total Procurement Value: \$ 393,750 plus tax Total Paid to Date: \$Nil	Open competitive	No modification
13	Deloitte Inc.	Digital Analytics and Data Governance Roadmap Development	September 6, 2023 to September 5, 2026	Total Procurement Value: \$180,000 plus tax (includes consulting & non-consulting) Total Paid to Date: \$60,000	Open competitive	No modifications